Online inquiry

IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1563MR)

This product GTTS-WQ1563MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets BMP10&GDF2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_014482.3; NM_016204.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27302; 2658
UniProt ID O95393; Q9UK05
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1563MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1853MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ9735MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JR-141
GTTS-WQ3611MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ5284MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD124
GTTS-WQ10380MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ14661MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ2730MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-139
GTTS-WQ10926MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MABT5102A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW